Amylin Pharmaceuticals, Inc. Release: BYDUREON™ Was Associated With Significant and Sustained Glycemic Control at Four Years

Published: Jun 11, 2012

PHILADELPHIA--(BUSINESS WIRE)--Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON™ (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.

Back to news